Pfizer History of Innovation and Controversy

Pfizer has been a trailblazer in the pharmaceutical industry, with a history of innovation that spans over 170 years. Founded in 1849 by Charles Pfizer and Charles Erhart, the company started as a small pharmaceutical laboratory in New York City.

Pfizer's early success was driven by its development of antiparasitic medicines, including the first commercial production of citric acid in 1859. This achievement marked a significant milestone in the company's history.

The company's commitment to innovation continued with the introduction of the first mass-produced penicillin in 1941, which revolutionized the treatment of bacterial infections.

Broaden your view: Takeda Pharmaceutical Company

Pfizer was founded as Charles Pfizer & Company in 1849 in Brooklyn, New York, by cousins Charles Pfizer and Charles F. Erhart, both of whom had emigrated from Germany to the United States in 1848.

The company focused on the manufacture of chemical compounds and found its first success with the development of an antiparasitic known as santonin.

A fresh viewpoint: Charles Schwab Corporation

Pfizer's fortunes climbed further with the production of citric acid, which had numerous industrial uses. This marked a significant milestone in the company's growth.

By 1906, Pfizer's annual sales topped $3 million, demonstrating the company's steady expansion.

Here's a brief timeline of Pfizer's early success:

The company's ability to adapt to changing circumstances was crucial to its success. During World War I, a global shortage of calcium citrate forced Pfizer to seek an alternative.

Pfizer's journey to becoming a global pharmaceutical leader began in the mid-20th century.

The company's pivot to pharmaceutical research and global expansion started in the 1950s, as it searched for new antibiotics with greater profit potential.

Pfizer discovered oxytetracycline in 1950, marking a significant shift from manufacturing fine chemicals to a research-based pharmaceutical company.

By the 1950s, Pfizer had established offices in several countries, including Belgium, Brazil, Canada, Cuba, Mexico, Panama, Puerto Rico, and the United Kingdom.

On a similar theme: West Pharmaceutical Services

In 1960, Pfizer moved its medical research laboratory operations out of New York City to a new facility in Groton, Connecticut.

Feldene, a prescription anti-inflammatory medication, became Pfizer's first product to reach $1 billion in revenue in 1980.

John Powers, Jr. took over as chief executive officer in 1965, succeeding John McKeen.

In the 21st century, Pfizer continued to expand and innovate.

The company received approval for Lyrica in 2004, an anticonvulsant and anxiolytic medication used to treat various conditions.

However, Pfizer faced a setback with the development of torcetrapib, a drug that was discontinued due to higher-than-expected mortality rates in clinical trials.

The company spent $3.3 million on investigations and legal fees between 2007 and 2010, recovering about $5.1 million.

Pfizer also hired customs and narcotics experts worldwide to track down counterfeit prescription drugs and pursue civil suits for trademark infringement.

In 2008, the company announced 275 job cuts at its manufacturing facility in Portage, Michigan.

Discover more: John Elkann

Pfizer has been on a buying spree over the years, acquiring several pharmaceutical companies to expand its portfolio. In 2000, it spent $110 billion to purchase Warner-Lambert, but had to divest itself of several minor products due to antitrust regulations.

Pfizer's next big acquisition was in 2003, when it bought Pharmacia, a deal that included Searle and SUGEN. The SUGEN facility was shut down soon after, but several of its programs were folded into Pfizer, including the cancer treatment drug sunitinib.

The acquisition of Wyeth in 2009 made Pfizer the world's largest pharmaceutical company, with a pneumococcal conjugate vaccine, Prevnar 13, being one of its key assets. This vaccine has been instrumental in reducing the incidence of invasive pneumococcal infections among children under age 5 in the United States.

Peter Rost's termination in 2005 was a result of his whistleblowing activities at Pfizer. He was a vice president in charge of the endocrinology division at Pharmacia before its acquisition by Pfizer.

Rost raised concerns internally about kickbacks and off-label marketing of Genotropin, Pharmacia's human growth hormone drug. Pfizer reported the Pharmacia marketing practices to the FDA and Department of Justice.

Pfizer kept Rost employed, but isolated him until the FCA suit was unsealed in 2005. The Justice Department declined to intervene, and Pfizer fired him.

Rost filed a wrongful termination suit against Pfizer, but Pfizer won a summary dismissal of the case.

Pfizer's acquisition history is a long and impressive one, with several major deals taking place in the early 2000s.

In June 2000, Pfizer acquired Warner-Lambert outright for $116 billion, creating what was then the second-largest pharmaceutical company worldwide.

Pfizer's acquisition of Pharmacia in 2003 was another significant deal, which included the acquisition of Searle and SUGEN. Searle developed several notable medications, including Flagyl and Celebrex.

SUGEN, a company focused on protein kinase inhibitors, had pioneered the use of ATP-mimetic small molecules to block signal transduction.

Worth a look: Acquisition of 21st Century Fox by Disney

The SUGEN facility was shut down in 2003 by Pfizer, with the loss of more than 300 jobs, and several programs were transferred to Pfizer.

These included sunitinib (Sutent), a cancer medication which was approved for human use by the FDA in January 2006.

Pfizer's acquisition of Wyeth in 2009 made it the largest pharmaceutical company in the world.

The acquisition of Wyeth provided Pfizer with a pneumococcal conjugate vaccine, trademarked Prevnar 13; this is used for the prevention of invasive pneumococcal infections.

Here are some key acquisitions and mergers made by Pfizer:

These acquisitions have significantly expanded Pfizer's product portfolio and made it the largest pharmaceutical company in the world.

Pfizer is the manufacturer and/or marketer of many well-known products.

The company's most recognizable brands include a list of pharmaceutical products that have been made available to the public.

Pfizer is the manufacturer and/or marketer of many well-known products.

Pfizer is a well-established pharmaceutical company with a wide range of products. They have a significant presence in the market with many recognizable brands.

Pfizer develops targeted therapies to treat various types of cancer, including bladder, breast, cervical, lung, and colorectal cancers, as well as hematological malignancies.

One notable example is the EMBARK trial, which showed improved metastasis-free survival in high-risk, non-metastatic prostate cancer patients, leading to the FDA approval of a combination therapy in 2023.

The TALAPRO-2 study explored treatments for metastatic prostate cancer with homologous recombination repair mutations, which are found in 25% of cases.

Here are some of Pfizer's key pharmaceutical products in oncology:

Pfizer also conducts research on precision medicine and immunotherapy to improve survival rates and quality of life for cancer patients.

Prempro is a hormone replacement therapy drug. In 2013, Pfizer announced a recall of five lots of Prempro due to low strength. Routine testing revealed the issue. This led to a recall of the affected lots.

Chantix is available in two dosages: 0.5 mg and 1 mg tablets.

The 0.5 mg and 1 mg tablets of Chantix were recalled by Pfizer in 2021 due to an increased cancer risk from high levels of N-nitroso-varenicline.

The recall was precautionary, as no cancer-related issues had been detected in testing of Chantix or with people taking the medication.

Pfizer faced lawsuits over Protonix, a medication that was promoted for unapproved uses by Wyeth, a company Pfizer acquired in 2009. Wyeth promoted Protonix in 2000 and 2001.

The U.S. Department of Justice held Wyeth accountable for these actions, leading to a $55 million settlement in 2013.

Pfizer also faced breast cancer lawsuits related to another medication, Prempro.

Pfizer is the manufacturer of Chantix, a smoking cessation drug that has been the subject of controversy. Chantix was voluntarily recalled in 2021 due to an increased cancer risk from high levels of an ingredient called N-nitroso-varenicline.

The recall was precautionary, as no cancer-related issues had been detected in testing or with people taking the drug. This highlights the importance of pharmaceutical companies taking proactive measures to ensure public safety.

About 3,000 people filed lawsuits against Pfizer, claiming Chantix caused suicidal thoughts and severe psychological disorders. The company set aside around $288 million to resolve these cases in 2013.

For your interest: Meyer Brothers Drug Company

Pfizer has been accused of aggressive pharmaceutical marketing. This is evident in the company's history of settlements and fines related to its marketing practices.

In 2009, Pfizer pleaded guilty to the illegal marketing of Bextra, an arthritis drug, and agreed to a $2.3 billion settlement. This was the largest healthcare fraud settlement at the time.

Pfizer promoted the sale of Bextra for several uses and dosages that the FDA specifically declined to approve due to safety concerns. The drug was pulled from the market in 2005.

People are suing Pfizer over Protonix, alleging the company failed to warn about the risk of kidney problems. In 2013, Pfizer agreed to pay $55 million to settle criminal charges.

Pfizer acquired Wyeth in 2009, which had promoted Protonix for unapproved uses in 2000 and 2001. The U.S. Department of Justice said this was a violation of the law.

Nearly 10,000 women filed Prempro breast cancer lawsuits against Pfizer, which the company settled for over $1 billion by 2012.

Pfizer has faced numerous lawsuits and recalls throughout its history. The company recalled the 0.5 mg and 1 mg tablets of its smoking cessation drug Chantix in June 2022 due to unacceptable levels of the cancer-causing compound N-nitroso-varenicline.

In 2013, Pfizer put nearly $288 million aside to settle claims related to Chantix, which had been linked to suicidal ideation and other psychological disorders. An estimated 3,000 people had filed suit against the company over the issue.

Pfizer also holds the dubious distinction of paying the largest settlement in the history of the U.S. Justice Department for health care fraud: $2.3 billion. This was finalized in 2009 after Pfizer subsidiary Pharmacia & Upjohn Company, Inc. pleaded guilty to misbranding the anti-inflammatory drug Bextra with intent to defraud or mislead.

Pfizer has faced numerous lawsuits and recalls since its founding. The company's history is marred by quality issues and poor packaging, leading to recalls of popular products.

In 2009, Pfizer paid the largest settlement in the history of the U.S. Justice Department for health care fraud: $2.3 billion. This settlement was finalized after Pfizer subsidiary Pharmacia & Upjohn Company, Inc. pleaded guilty to misbranding the anti-inflammatory drug Bextra.

The company has also faced lawsuits over neurology treatments Lyrica and Geodon, transplant drug Rapamune, its Celebrex anti-inflammatory drug, and “low-T” drug Depo-Testosterone. Pfizer settled an estimated 13,000 lawsuits for $1.2 billion after allegations that hormone replacement drug Prempro increased the risk of breast cancer.

Pfizer recalled the 0.5 mg and 1 mg tablets of its popular smoking cessation drug Chantix in June 2022 due to unacceptable levels of the cancer-causing compound N-nitroso-varenicline. The recall was expanded further in 2023.

In 2013, Pfizer put nearly $288 million aside to settle claims related to Chantix. Years earlier, an estimated 3,000 people filed suit against Pfizer over Chantix, alleging suicidal ideation and other psychological disorders.

Pfizer has faced numerous lawsuits over the years, with thousands of cases dismissed by courts.

The company has also agreed to settle cases involving claims of illegal marketing and health care fraud.

Pfizer pleaded guilty to the illegal marketing of arthritis drug valdecoxib (Bextra) in 2009 and agreed to a $2.3 billion settlement.

This settlement was the largest health care fraud settlement at the time and included $1.195 billion in criminal penalties.

Pfizer entered a corporate integrity agreement with the Office of Inspector General, requiring the company to make substantial structural reforms.

The company was also required to publish its post-approval commitments and a searchable database of payments to physicians on its website.

In 2012, Pfizer settled a lawsuit with Brigham Young University over the development of Celebrex, agreeing to pay $450 million.

This settlement came after a six-year battle over claims that Pfizer did not give credit or compensation to Dr. Daniel L. Simmons, who discovered an enzyme that led to the development of Celebrex.

Pfizer joined forces with BioNTech in March 2020 to develop an mRNA vaccine for COVID-19, a devastating virus that killed millions worldwide.

Pfizer used $2 billion of the company's money to develop the vaccine, opting to avoid government interference.

The company developed four vaccine variations and two were given the go-ahead for human testing by the Food and Drug Administration.

One of the vaccines offered a 95% efficacy rate, announced by Pfizer in November 2020.

The vaccine was quickly approved by several nations, including the United States.

Pfizer complemented its COVID-19 vaccine with an oral antivirus treatment called Paxlovid in 2021.

Paxlovid proved to be effective for reducing symptom severity and keeping COVID-19 patients out of the hospital.

Pfizer was accused by The Bureau of Investigative Journalism of employing "high-level bullying" against at least two Latin American countries during negotiations to acquire COVID-19 vaccines.

The company requested that the countries put sovereign assets as collateral for payments, resulting in a months-long delay in one country and a complete failure to reach agreements with two other countries.

Pfizer was accused of falsifying data, unblinding patients, and employing inadequately trained vaccinators in its pivotal phase III trial.

The regional director who reported these issues was fired by Ventavia Research Group, the subcontractor hired by Pfizer.

The European Medicines Agency stated that the deficiencies identified did not jeopardize the quality and integrity of the data from the main Comirnaty trial.

However, Pfizer executive Janine Small testified that the company had not evaluated the Pfizer-BioNTech COVID-19 vaccine for its ability to reduce transmission of the SARS-CoV-2 virus prior to its release to the general public.

See what others are reading: Flagstar Bank Data Breach

Pfizer has a long history of innovation in research and development, dating back to the 1950s when the company discovered oxytetracycline, a new antibiotic that shifted its focus from fine chemicals to pharmaceuticals.

In the 1960s, Pfizer established an animal health division with a 700-acre farm and research facility in Terre Haute, Indiana, and expanded internationally, opening offices in several countries including Belgium, Brazil, Canada, and the United Kingdom.

The company has continued to invest in research and development, launching Feldene, a prescription anti-inflammatory medication, in 1980, which became its first product to reach $1 billion in revenue.

Worth a look: DuPont Central Research

Pfizer's shift from a chemical manufacturer to a research-based pharmaceutical company began in 1950 with the discovery of oxytetracycline, a new antibiotic with greater profit potential.

This discovery marked a significant turning point in the company's history, as it enabled Pfizer to expand its product line and increase its revenue.

In 1959, Pfizer entered the animal health arena, establishing a research facility inside a 700-acre farm in Terre Haute, Indiana, and supporting it with a comprehensive animal health division.

Pfizer's international expansion accelerated in the 1950s, with the establishment of facilities in Canada, the United Kingdom, Mexico, and other countries.

By 1960, Pfizer had transferred its New York research operation to a new facility in Groton, Connecticut, a move that would allow the company to continue its research and development efforts.

Pfizer's animal health division went on to acquire other companies, including Pharmacia Corp. and CSL Animal Health, and was eventually renamed Zoetis in 2012, becoming a major player in the animal health field.

The company's first product to reach $1 billion in revenue was Feldene (piroxicam), a prescription anti-inflammatory medication launched in 1980.

You might like: The New York Times Company

AI Collaboration in Clinical Trials is revolutionizing the way research is conducted. Pfizer's partnership with Saama is a prime example of this, having expanded their multi-year agreement to integrate AI-driven solutions across Pfizer's R&D portfolio.

The partnership initially focused on automating data review processes with the Smart Data Quality (SDQ) platform, which was developed during Pfizer's COVID-19 vaccine trials. This platform has been instrumental in streamlining data review and accelerating regulatory submissions across global studies.

Pfizer's collaboration with Saama has also introduced the Biometrics Research and Analysis Information Network, enabling faster statistical programming, biostatistics workflows, and submission-ready outputs. This has significantly improved the efficiency of clinical trials.

By leveraging AI, Pfizer is able to process and analyze vast amounts of data quickly and accurately, leading to faster and more informed decision-making.

Obesity treatment research is advancing, with Pfizer's danuglipron showing promise in initial trials. Danuglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist.

The initial twice-daily formulation of danuglipron demonstrated potential for weight loss and blood sugar management. A once-daily modified-release version has been identified for further study.

Trials involving 1,400 participants showed a suitable pharmacokinetic profile and no significant safety issues for the once-daily formulation. Dose optimization trials are planned for late 2024 to support large-scale registration studies.

Pfizer has received numerous accolades and recognitions worldwide for its efforts in fostering an inclusive and equitable work environment.

Pfizer earned a 100% score from the Human Rights Campaign (2025) on the Corporate Equality Index for LGBTQ workplace equality.

It's impressive to see a company like Pfizer take the lead in promoting diversity and inclusion in the workplace.

Pfizer was named a "Best Place to Work for Disability Inclusion" in the Disability Equality Index (2024) and received awards such as Top Diverse Employer, Top Hispanic Employer, and Top Disability-Friendly Company by DiversityComm, Inc. (2024).

Readers also liked: Truist Financial Reports Q3 2024 Earnings.

These recognitions demonstrate Pfizer's commitment to creating a welcoming environment for all employees.

Pfizer was also recognized as one of "America's Greatest Workplaces" by Newsweek (2023) and was included in the top 10 of the "World's Most Admired Companies" by Fortune (2023).

It's clear that Pfizer's efforts to promote diversity and inclusion have paid off in a big way.

Pfizer faced controversy over its COVID-19 vaccine negotiations with Latin American countries. These countries were reportedly asked to put sovereign assets as collateral for payments, resulting in a months-long delay in one country and a complete failure to reach agreements with Argentina and Brazil.

In 2021, a whistleblower from the Ventavia Research Group, a subcontractor of Pfizer, came forward with allegations of data falsification, unblinded patients, and inadequately trained vaccinators in Pfizer's pivotal phase III trial.

The European Medicines Agency stated that the deficiencies identified did not jeopardize the quality and integrity of the data from the main Comirnaty trial. However, this does not change the fact that such issues occurred.

Pfizer executive Janine Small testified in 2022 that the company had not evaluated the Pfizer-BioNTech COVID-19 vaccine for its ability to reduce transmission of the SARS-CoV-2 virus prior to its release. This admission was described as "scandalous" by Dutch MEP Rob Roos.